Search tips
Search criteria 


Logo of jdsrThe Japanese Dental Science Review
Jpn Dent Sci Rev. 2017 February; 53(1): 18–24.
Published online 2016 June 27. doi:  10.1016/j.jdsr.2016.06.001
PMCID: PMC5390332

Phospholipase C-related catalytically inactive protein can regulate obesity, a state of peripheral inflammation


Obesity is defined as abnormal or excessive fat accumulation. Chronic inflammation in fat influences the development of obesity-related diseases. Many reports state that obesity increases the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, sleep apnea, and breast, prostate and colon cancers, leading to increased mortality. Obesity is also associated with chronic neuropathologic conditions such as depression and Alzheimer's disease. However, there is strong evidence that weight loss reduces these risks, by limiting blood pressure and improving levels of serum triglycerides, total cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol. Prevention and control of obesity is complex, and requires a multifaceted approach. The elucidation of molecular mechanisms driving fat metabolism (adipogenesis and lipolysis) aims at developing clinical treatments to control obesity. We recently reported a new regulatory mechanism in fat metabolism: a protein phosphatase binding protein, phospholipase C-related catalytically inactive protein (PRIP), regulates lipolysis in white adipocytes and heat production in brown adipocytes via phosphoregulation. Deficiency of PRIP in mice led to reduced fat accumulation and increased energy expenditure, resulting in a lean phenotype. Here, we evaluate PRIP as a new therapeutic target for the control of obesity.

Keywords: Brown adipocyte, Energy expenditure, Inflammation, Lipolysis, Obesity, White adipocyte

1. Introduction

The World Health Organization points out that obesity is currently one of the most blatantly visible, yet most neglected, public health problem. If immediate action is not taken, millions will suffer from an array of serious health disorders linked to obesity [1]. Recent studies have demonstrated that obesity is associated with some of the cellular mechanisms of inflammation and overproduction of proinflammatory cytokines. The pathological conditions of adipose tissue under hypertrophy (cell size increase) and hyperplasia (cell number increase) are low-grade and chronic inflammation may lead to the development of various co-morbidities, such as hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, and cancers [2], [3].

Inflammation is a physiological response necessary to restore homeostasis altered by diverse stimuli; however, an excessive inflammatory response or a chronically established inflammation state can cause systemic deleterious effects. For instance, periodontal disease is a source of chronic inflammation and was found to play a causative or contributory role in the pathogenesis of systemic diseases [4]. Furthermore, epidemiological studies have recently shown high co-morbidity between mental illness and peripheral chronic inflammatory diseases, including obesity and periodontitis [2], [3], [4]. Therefore, the control of inflammation in peripheral organ diseases is paramount for the protection and promotion of human health.

Adipose tissues are an insidious source of inflammation in morbid obesity. We have elucidated a new regulatory mechanism in lipid and energy metabolisms within adipocytes to control obesity. Phospholipase C-related catalytically inactive protein (PRIP), a new functional molecule in lipolysis, is involved in a triacylglycerol (TAG) degradation pathway via intracellular phosphoregulation. Here, we discuss the regulation of TAG hydrolysis via PRIP.

2. Fat metabolism in adipocytes

2.1. Regulation of fat metabolism

There are two types of adipose tissues, white adipose tissue (WAT) and brown adipose tissue (BAT), which have antagonistic functions [5]. WAT is the major energy storage component in higher eukaryotes. The primary purposes of this tissue are synthesis and storage of TAG in periods of energy excess, and hydrolysis of TAG to generate fatty acids for use by other organs during periods of energy deprivation. In contrast, BAT directly dissipates the chemical energy contained in fatty acids as heat via uncoupling protein 1 (UCP1) as a defense against cold and excessive feeding (Fig. 1). Understanding of molecular mechanisms driving adipocyte-specific TAG synthesis and hydrolysis, and/or governing energy expenditure in brown adipocytes is critical to explain the development of obesity.

Figure 1
Fat metabolism in adipocytes. WAT is the primary energy storage depot, accumulating fuel reserves in the form of TAG during times of energy excess, and releasing FFAs and glycerol during periods of energy deprivation. BAT is specialized in dissipating ...

2.2. Activation of lipolysis by catecholamine signaling

Although TAG synthesis occurs in multiple tissues, TAG lipolysis during periods of energy demand predominantly occurs in adipose tissues. The hydrolytic action by lipases in WAT is rapid, and free fatty acids (FFAs) are supplied to other organs to meet the energy requirements of the organism [6]. The TAG degradation process is regulated by several molecules, including anti-comparative gene identification 58 (CGI-58), perilipin (lipid droplet-associated protein), and the lipolytic enzymes, adipocyte triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and monoacylglycerol lipase (MGL). These lipolytic enzymes and modulators promote the hydrolysis of TAG, resulting in the formation of FFAs and glycerol in adipocytes (Fig. 1).

The intracellular degradation of TAG is catalyzed by a cascade of lipolytic enzymes (Fig. 2). Under basal condition, at the surface of lipid droplets, perilipin, a master lipolysis regulator of stored TAG, sequesters CGI-58, a coactivator protein of ATGL [7]. This prevents sequential hydrolysis of stored TAG. Under starvation conditions, sympathetic nerves are activated, which initiates adipose lipolysis. Catabolic hormone adrenaline, a catecholamine, binds to β-adrenergic receptors on adipocyte plasma membrane and triggers a G protein-mediated cascade that activates adenylate cyclase, which itself increases levels of cAMP and activates protein kinase A (PKA). PKA phosphorylates perilipin at multiple sites. Subsequently, CGI-58 is released from perilipin, associates with, and fully activates ATGL. This ATGL hydrolyzes TAG into diacylglycerol (DAG). The activated PKA also phosphorylates HSL, located in the cytosol. Phosphorylated HSL is translocated from the cytosol to the surfaces of intracellular lipid droplets and is tethered on the lipid droplets by the phosphorylated perilipin. Subsequently, activated (phosphorylated) HSL hydrolyzes DAG into monoacylglycerol, followed by degradation into a FFA and glycerol by MGL in the final step of lipolysis. FFAs are released into the blood stream, where they bind to albumin for transport to surrounding tissues requiring energy. Glycerol is also transported into the bloodstream and is absorbed by the liver or kidneys, where it is converted to glycerol 3-phosphate by the enzyme glycerol kinase.

Figure 2
Possible mechanism by which the PRIP and protein-phosphatase complex mediates lipolysis regulation. Lipolysis in adipocytes is mediated by the activation of a PKA-mediated pathway. The process is regulated by lipases (HSL and ATGL) and other modulatory ...

Perilipin is phosphorylated at multiple sites by PKA, a process essential for the translocation of HSL to lipid droplets. Furthermore, this response corresponds to the phosphorylation of HSL and the acceleration of lipolysis promoted by the sympathetic nervous system in adipocytes. HSL can be phosphorylated at least on five serine residues (563, 565, 600, 659, and 660 of the rat sequence) in vitro [7]. Ser-563, Ser-659, and Ser-660 are the major PKA phosphorylation sites responsible for activating HSL. Dephosphorylation of HSL and perilipin by protein phosphatases can also play an important role in the regulation of lipolysis.

2.3. Inhibition of lipolysis by insulin receptor signaling

Insulin, the major anabolic hormone, can restrain lipolysis and promote fat storage in adipose tissues during the postprandial period. Protein phosphatases are involved in the antilipolytic effect of insulin. Insulin receptor tyrosine kinase phosphorylates insulin receptor substrate (IRS)-1, which recruits and activates phosphoinositide 3-kinase (PI3K) leading to the production of phosphatidylinositol-3,4,5-triphosphate (PIP3). AKT (also known as protein kinase B) is recruited onto the membrane by binding with PIP3 via its pleckstrin homology domain, and is subsequently phosphorylated and activated by PDK1. AKT thus phosphorylates two important targets, phosphodiesterase 3B [8] and protein phosphatases (protein phosphatase 1, protein phosphatase 2A, and protein phosphatase 2C) [9], [10], to allow the downregulation of lipolysis. Consequently, lipolysis in adipocytes is attenuated. In addition, insulin signaling-independent dephosphorylation of HSL and perilipin may be involved in the inactivation of lipolysis after activation of the sympathetic nervous system; however, this mechanism has not yet been elucidated.

3. A new molecule for the regulation of lipolysis in adipocytes

3.1. Identification of PRIP

PRIP was originally purified as an inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] binding protein from the cytosol fraction of the rat brain, but has since been isolated from the membrane fraction of the brain [11], [12]. PRIP has similar domain organization to phospholipase C-δ1 [13], [14], but lacks the enzymatic activity of phospholipase C [15] (Fig. 3). There are two isoforms in mammals; PRIP1, expressed mainly in the brain, and PRIP2, ubiquitously expressed [16], [17]. Both PRIPs are expressed in white and brown adipose tissues [18], [19]. Experiments exploring a PRIP binding partner revealed that PRIP can bind to PP1 and PP2A [20], [21], [22], [23], [24], [25], Ins(1,4,5)P3 and inositol lipids [11], [12], [26], [27], [28], gamma aminobutyric acid type A receptor-associated protein (GABARAP) [29], [30], [31], [32], [33], β subunit of GABAA receptor [21], and phosphorylated AKT [34]. After verifying the relationship between PRIP and these binding partners using Prip-KO mice, we elucidated the role of PRIP in cells; PRIP is involved in Ins(1,4,5)P3/Ca2+ signaling [35], [36], dephosphoregulation of intracellular signaling molecules [18], [19], [21], [22], intracellular trafficking of GABAA receptors or insulin secretory vesicles [29], [30], [33], [37], [38], [39], [40], and regulation of autophagy [31], [32].

Figure 3
Phospholipase C-related catalytically inactive protein. PRIP has a similar domain organization to PLCδ1. The binding partners of PRIP are shown. The numbers represent amino acid residues. IP3, inositol 1,4,5-trisphosphate; PP1, protein phosphatase ...

3.2. Lean phenotype of Prip-KO mice

Studies in Prip-null knockout (Prip-KO) mice have confirmed the importance of this molecule in the lipolysis of TAG [18], [19]. Regular diet (RD)-fed Prip-KO mice exhibited a lean phenotype with smaller WAT in size and weight. The Prip-KO mice showed slightly more food intake than wild-type mice. The serum cholesterol and TAG levels were significantly increased in Prip-KO mice compared with wild-type control mice. However, ectopic lipid accumulation was not observed in the liver of Prip-KO mice. In high-fat diet (HFD)-feeding experiments, Prip-KO mice showed less body weight increase, and their body weight at 20 weeks of age was lower than that of wild-type controls. The Prip-KO mice obviously displayed leanness with small-sized WAT. These results allowed associating the lean phenotype of Prip-KO mice with the alteration of fat metabolism in adipocytes.

3.3. PRIP and protein phosphatase regulate adrenaline-induced lipolysis in adipocytes

Our investigations showed that phosphorylation of HSL and perilipin in RD-fed Prip-KO WAT was upregulated under both non-fasting and fasting conditions compared with wild-type mice. In response to adrenaline stimulation, or under starvation conditions, the cytosolic protein PRIP was translocated to lipid droplets in mouse white adipocytes; in the meantime, levels of PP1 and PP2A, which bind to PRIP, were increased in the lipid droplet fractions (Fig. 2). Consistently, after adrenaline stimulation, time-dependent dephosphorylation change of HSL was observed in wild-type adipocytes, but not in Prip-KO adipocytes. From these findings, we proposed a model of PRIP-mediated phosphoregulation of lipolysis in adipocytes (Fig. 2). Once starvation or stress signals trigger the activation of PKA in adipocytes, HSL is phosphorylated, translocated to lipid droplets, and activates hydrolysis of lipids. The signal also induces the translocation of PRIP and protein phosphatase complex to lipid droplets, which promotes the dephosphorylation of HSL and attenuates lipolysis. These sequential events yield a sharp transient activation of lipolysis to provide a fine-tuning of catabolic hormonal regulation in adipocytes.

3.4. PRIP regulates energy metabolism

Compared to wild-type mice, HFD-fed Prip-KO mice showed more moderate body weight increase, greater glucose tolerance, and higher insulin sensitivity. This underlined a protection mechanism against HFD-induced obesity in Prip-KO mice [19]. Histological analyses showed that ectopic lipid accumulation in the liver was strongly decreased in HFD-fed Prip-KO mice. Consistently, energy expenditure and body temperature were higher in Prip-KO mice than in wild-type mice.

Many studies have shown that BAT contributes to adult human obesity, and activation of UCP1-mediated thermogenesis in BAT prevents obesity and diabetes [5], [41], [42]. Brown adipocytes directly dissipate the chemical energy in fatty acids as heat through uncoupling protein 1 (UCP1) (Fig. 4). In both white and brown adipocytes, sympathetic hyperactivity causes β-adrenergic receptor-induced PKA activation, followed by activation of lipolysis. FFAs are used not only as substrates for oxidative respiration but also as allosteric activators of UCP1. In addition, PKA activation followed by elevated intracellular FFAs activates UCP1-mediated heat generation and regulates thermogenesis through transcriptional control in BAT [19], [43], [44], [45]. PKA mediates the phosphorylation of cAMP response element-binding protein (CREB) and p38 mitogen-activated protein kinase (p38 MAPK), followed by activation of the gene expression of peroxisome proliferator-activated receptor (PPAR)-γ, coactivator-1α (PGC1α), PPARα, and PPARδ, to finally trigger Ucp1 gene expression in brown adipocytes [5], [45], [46], [47]. The Prip-KO mouse study demonstrated that PRIP regulates β-adrenergic receptor signaling-induced UCP1-dependent thermogenesis in BAT through phosphoregulation of HSL and perilipin.

Figure 4
PRIP regulates thermogenesis in brown adipocytes. Sympathetic nerve stimulation enhances receptor-mediated PKA activation in brown adipocytes. PKA induces UCP1 activation through at least two pathways. (i) PKA facilitates the phosphorylation of HSL and ...

4. Chronic peripheral inflammation is a risk factor for mental illness

Obesity is a chronic inflammatory state that originates locally in adipose tissues as a consequence of excessive fat deposition, and is later reflected in increased systemic circulating levels of proinflammatory proteins. Markers of abdominal obesity (e.g., waist circumference) seem to be strongly associated with inflammatory markers, and a reduction in the adipose tissue mass reduces the ability of adipose tissues to produce proinflammatory cytokines, TNFα, IL-6, IL-8, and leptin [48], [49], [50]. Dental diseases such as periodontitis are also associated with high levels of systemic inflammation [51], a significant predictor of inflammatory illnesses, such as cardiovascular disease [52], [53] and diabetes [54]. Moreover, many studies show that peripheral chronic inflammation increases the risk of mental illness [3], [4]. Depressive patients have high concentration of proinflammatory cytokines (i.e., IL-1β, IL-6, and TNF-α) in blood [55].

In animal models using rodents, systemic inflammation induces “depression-like behavior” such as anhedonia, reduced appetite, helplessness, apathy, and social withdrawal [56]. We and other groups showed that peripheral injection of lipopolysaccharide induced anorexia via the increase of hypothalamic IL-1β and IL-6 [57], [58]. The circulating proinflammatory cytokines can enter the central nervous system in areas where the blood–brain barrier is incomplete, or can be transported into the brain tissues by carrier-mediated mechanisms across the blood–brain barrier. Therefore, proinflammatory cytokines in peripheral blood stream communicate with the brain and cause the activation of microglia and astrocytes. In the case of microglia, TNF-α activated indoleamine 2,3-dioxygenase, an enzyme enabling the production of kynurenine from tryptophan, the origin of serotonin [57]. This resulted in decreasing the serotonin synthesis pathway and promoting kynurenine production, itself further metabolized into quinolinic acid. Quinolinic acid is an N-methyl-d-aspartate (NMDA) receptor agonist, which induces depression-like behavior. Therefore, peripheral inflammation, mediated by obesity or oral infectious diseases, induces the decrease of serotonin and the increase of neurotoxic quinolinic acid, potentially causing mental illness. Therefore, the control of peripheral inflammation is crucial for maintaining a healthy life.

5. Conclusion

We recently defined PRIP as a new modulator within the lipolysis pathway, which negatively regulates the phosphorylation of perilipin and HSL in WAT, and can also regulate thermogenesis in BAT via fatty acid production. Importantly, deficiency of PRIP in mice exhibited anti-obesity phenotypes. Therefore, PRIP represents a potential therapeutic target for the control of obesity. Since anti-obesity therapy can reduce the risks of many serious health disorders including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, and mental disorders, further comprehensive studies of PRIP signaling will contribute to the development of new therapeutic targets aimed at tackling excess body fat accumulation to ensure a healthy life.

Conflict of interest

The authors declare no conflict of interest.


Our works have been supported by KAKENHI from Japan Society for the Promotion of Science (Grant numbers: 15K19731 to Y.Y., 15H06433 to K.O., and 26670809 to T.K.).


1. World Health Organization. Controlling the global obesity epidemic.
2. Rodríguez-Hernández H., Simental-Mendía L.E., Rodríguez-Ramírez G., Reyes-Romero M.A. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. 2013;2013:678159. [PubMed]
3. Emanuela F., Grazia M., Marco de R., Maria Paola L., Giorgio F., Marco B. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab. 2012;2012:476380. [PubMed]
4. Berk M., Williams L.J., Jacka F.N., O’Neil A., Pasco J.A., Moylan S. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200. [PubMed]
5. Harms M., Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013;19:1252–1263. [PubMed]
6. Ahmadian M., Duncan R.E., Sul H.S. The skinny on fat: lipolysis and fatty acid utilization in adipocytes. Trends Endocrinol Metab. 2009;20:424–428. [PubMed]
7. Lampidonis A.D., Rogdakis E., Voutsinas G.E., Stravopodis D.J. The resurgence of Hormone-Sensitive Lipase (HSL) in mammalian lipolysis. Gene. 2011;477:1–11. [PubMed]
8. Wijkander J., Landström T.R., Manganiello V., Belfrage P., Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology. 1998;139:219–227. [PubMed]
9. Ragolia L., Begum N. Protein phosphatase-1 and insulin action. Mol Cell Biochem. 1998;182:49–58. [PubMed]
10. Olsson H., Belfrage P. The regulatory and basal phosphorylation sites of hormone-sensitive lipase are dephosphorylated by protein phosphatase-1, 2A and 2C but not by protein phosphatase-2B. Eur J Biochem. 1987;168:399–405. [PubMed]
11. Kanematsu T., Takeya H., Watanabe Y., Ozaki S., Yoshida M., Koga T. Putative inositol 1,4,5-trisphosphate binding proteins in rat brain cytosol. J Biol Chem. 1992;267:6518–6525. [PubMed]
12. Yoshida M., Kanematsu T., Watanabe Y., Koga T., Ozaki S., Iwanaga S. D-myo-inositol 1,4,5-trisphosphate-binding proteins in rat brain membranes. J Biochem. 1994;115:973–980. [PubMed]
13. Yagisawa H., Hirata M., Kanematsu T., Watanabe Y., Ozaki S., Sakuma K. Expression and characterization of an inositol 1,4,5-trisphosphate binding domain of phosphatidylinositol-specific phospholipase C-δ 1. J Biol Chem. 1994;269:20179–20188. [PubMed]
14. Kanematsu T., Misumi Y., Watanabe Y., Ozaki S., Koga T., Iwanaga S. A new inositol 1,4,5-trisphosphate binding protein similar to phospholipase C-δ1. Biochem J. 1996;313:319–325. [PubMed]
15. Kanematsu T., Yoshimura K., Hidaka K., Takeuchi H., Katan M., Hirata M. Domain organization of p130, PLC-related catalytically inactive protein, and structural basis for the lack of enzyme activity. Eur J Biochem. 2000;267:2731–2737. [PubMed]
16. Matsuda M., Kanematsu T., Takeuchi H., Kukita T., Hirata M. Localization of a novel inositol 1,4,5-trisphosphate binding protein, p130 in rat brain. Neurosci Lett. 1998;257:97–100. [PubMed]
17. Uji A., Matsuda M., Kukita T., Maeda K., Kanematsu T., Hirata M. Molecules interacting with PRIP-2, a novel Ins(1,4,5)P3 binding protein type 2: comparison with PRIP-1. Life Sci. 2002;72:443–453. [PubMed]
18. Okumura T., Harada K., Oue K., Zhang J., Asano S., Hayashiuchi M. Phospholipase C-related catalytically inactive protein (PRIP) regulates lipolysis in adipose tissue by modulating the phosphorylation of hormone-sensitive lipase. PLoS One. 2014;9:e100559. [PubMed]
19. Oue K., Zhang J., Harada-Hada K., Asano S., Yamawaki Y., Hayashiuchi M. Phospholipase C-related catalytically inactive protein is a new modulator of thermogenesis promoted by β-adrenergic receptors in brown adipocytes. J Biol Chem. 2016;291:4185–4196. [PubMed]
20. Yoshimura K., Takeuchi H., Sato O., Hidaka K., Doira N., Terunuma M. Interaction of p130 with, and consequent inhibition of, the catalytic subunit of protein phosphatase 1α J Biol Chem. 2001;276:17908–17913. [PubMed]
21. Terunuma M., Jang I.S., Ha S.H., Kittler J.T., Kanematsu T., Jovanovic J.N. GABAA receptor phospho-dependent modulation is regulated by phospholipase C-related inactive protein type 1, a novel protein phosphatase 1 anchoring protein. J Neurosci. 2004;24:7074–7084. [PubMed]
22. Kanematsu T., Yasunaga A., Mizoguchi Y., Kuratani A., Kittler J.T., Jovanovic J.N. Modulation of GABAA receptor phosphorylation and membrane trafficking by phospholipase C-related inactive protein/protein phosphatase 1 and 2A signaling complex underlying brain-derived neurotrophic factor-dependent regulation of GABAergic inhibition. J Biol Chem. 2006;281:22180–22189. [PubMed]
23. Yanagihori S., Terunuma M., Koyano K., Kanematsu T., Ho Ryu S., Hirata M. Protein phosphatase regulation by PRIP, a PLC-related catalytically inactive protein implications in the phospho-modulation of the GABAA receptor. Adv Enzyme Regul. 2006;46:203–222. [PubMed]
24. Kanematsu T., Fujii M., Mizokami A., Kittler J.T., Nabekura J., Moss S.J. Phospholipase C-related inactive protein is implicated in the constitutive internalization of GABAA receptors mediated by clathrin and AP2 adaptor complex. J Neurochem. 2007;101:898–905. [PubMed]
25. Sugiyama G., Takeuchi H., Nagano K., Gao J., Ohyama Y., Mori Y. Regulated interaction of protein phosphatase 1 and protein phosphatase 2A with phospholipase C-related but catalytically inactive protein. Biochemistry. 2012;51:3394–3403. [PubMed]
26. Takeuchi H., Kanematsu T., Misumi Y., Yaakob H.B., Yagisawa H., Ikehara Y. Localization of a high-affinity inositol 1,4,5-trisphosphate/inositol 1,4,5,6-tetrakisphosphate binding domain to the pleckstrin homology module of a new 130 kDa protein: characterization of the determinants of structural specificity. Biochem J. 1996;318:561–568. [PubMed]
27. Takeuchi H., Kanematsu T., Misumi Y., Sakane F., Konishi H., Kikkawa U. Distinct specificity in the binding of inositol phosphates by pleckstrin homology domains of pleckstrin, RAC-protein kinase, diacylglycerol kinase and a new 130 kDa protein. Biochim Biophys Acta. 1997;1359:275–285. [PubMed]
28. Gao J., Takeuchi H., Zhang Z., Fujii M., Kanematsu T., Hirata M. Binding of phospholipase C-related but catalytically inactive protein to phosphatidylinositol 4,5-bisphosphate via the PH domain. Cell Signal. 2009;21:1180–1186. [PubMed]
29. Kanematsu T., Jang I.S., Yamaguchi T., Nagahama H., Yoshimura K., Hidaka K. Role of the PLC-related, catalytically inactive protein p130 in GABAA receptor function. EMBO J. 2002;21:1004–1011. [PubMed]
30. Mizokami A., Kanematsu T., Ishibashi H., Yamaguchi T., Tanida I., Takenaka K. Phospholipase C-related inactive protein is involved in trafficking of gamma2 subunit-containing GABAA receptors to the cell surface. J Neurosci. 2007;27:1692–1701. [PubMed]
31. Umebayashi H., Mizokami A., Matsuda M., Harada K., Takeuchi H., Tanida I. Phospholipase C-related catalytically inactive protein, a novel microtubule-associated protein 1 light chain 3-binding protein, negatively regulates autophagosome formation. Biochem Biophys Res Commun. 2013;432:268–274. [PubMed]
32. Harada-Hada K., Harada K., Kato F., Hisatsune J., Tanida I., Ogawa M. Phospholipase C-related catalytically inactive protein participates in the autophagic elimination of Staphylococcus aureus infecting mouse embryonic fibroblasts. PLoS One. 2014;9:e98285. [PubMed]
33. Asano S., Nemoto T., Kitayama T., Harada K., Zhang J., Harada K. Phospholipase C-related catalytically inactive protein (PRIP) controls KIF5B-mediated insulin secretion. Biol Open. 2014;3:463–474. [PubMed]
34. Fujii M., Kanematsu T., Ishibashi H., Fukami K., Takenawa T., Nakayama K.I. Phospholipase C-related but catalytically inactive protein is required for insulin-induced cell surface expression of gamma-aminobutyric acid type A receptors. J Biol Chem. 2010;285:4837–4846. [PubMed]
35. Takeuchi H., Oike M., Paterson H.F., Allen V., Kanematsu T., Ito Y. Inhibition of Ca2+ signalling by p130, a phospholipase-C-related catalytically inactive protein: critical role of the p130 pleckstrin homology domain. Biochem J. 2000;349:357–368. [PubMed]
36. Harada K., Takeuchi H., Oike M., Matsuda M., Kanematsu T., Yagisawa H. Role of PRIP-1, a novel Ins(1,4,5)P3 binding protein, in Ins(1,4,5)P3-mediated Ca2+ signaling. J Cell Physiol. 2005;202:422–433. [PubMed]
37. Mizokami A., Tanaka H., Ishibashi H., Umebayashi H., Fukami K., Takenawa T. GABAA receptor subunit alteration-dependent diazepam insensitivity in the cerebellum of phospholipase C-related inactive protein knockout mice. J Neurochem. 2010;114:302–310. [PubMed]
38. Kitayama T., Morita K., Sultana R., Kikushige N., Migita K., Ueno S. Phospholipase C-related but catalytically inactive protein modulates pain behavior in a neuropathic pain model in mice. Mol Pain. 2013;9:23. [PubMed]
39. Toyoda H., Saito M., Sato H., Tanaka T., Ogawa T., Yatani H. Enhanced desensitization followed by unusual resensitization in GABAA receptors in phospholipase C-related catalytically inactive protein-1/2 double-knockout mice. Pflugers Arch. 2015;467:267–284. [PubMed]
40. Toyoda H., Saito M., Sato H., Kawano T., Kawakami S., Yatani H. Enhanced lateral inhibition in the barrel cortex by deletion of phospholipase C-related catalytically inactive protein-1/2 in mice. Pflugers Arch. 2015;467:1445–1456. [PubMed]
41. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., Bouvy N.D. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–1508. [PubMed]
42. Virtanen K.A., Lidell M.E., Orava J., Heglind M., Westergren R., Niemi T. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–1525. [PubMed]
43. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359. [PubMed]
44. Fedorenko A., Lishko P.V., Kirichok Y. Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell. 2012;151:400–413. [PubMed]
45. Mottillo E.P., Bloch A.E., Leff T., Granneman J.G. Lipolytic products activate peroxisome proliferator-activated receptor (PPAR) α and δ in brown adipocytes to match fatty acid oxidation with supply. J Biol Chem. 2012;287:25038–25048. [PubMed]
46. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829–839. [PubMed]
47. Cao W., Daniel K.W., Robidoux J., Puigserver P., Medvedev A.V., Bai X. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol. 2004;24:3057–3067. [PubMed]
48. de Heredia F.P., Gómez-Martínez S., Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71:332–338. [PubMed]
49. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69:29–35. [PubMed]
50. Arvidsson E., Viguerie N., Andersson I., Verdich C., Langin D., Arner P. Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes. 2004;53:1966–1971. [PubMed]
51. Amar S., Gokce N., Morgan S., Loukideli M., Van Dyke T.E., Vita J.A. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol. 2003;23:1245–1249. [PubMed]
52. Kinane D.F., Lowe G.D. How periodontal disease may contribute to cardiovascular disease. Periodontology. 2000;23:121–126. [PubMed]
53. Humphrey L.L., Fu R., Buckley D.I., Freeman M., Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and metaanalysis. J Gen Intern Med. 2008;23:2079–2086. [PubMed]
54. Saremi A., Nelson R.G., Tulloch-Reid M., Hanson R.L., Sievers M.L., Taylor G.W. Periodontal disease and mortality in type 2 diabetes. Diabetes Care. 2005;28:27–32. [PubMed]
55. Nishida A., Hisaoka K., Zensho H., Uchitomi Y., Morinobu S., Yamawaki S. Antidepressant drugs and cytokines in mood disorders. Int Immunopharmacol. 2002;2:1619–1626. [PubMed]
56. Dantzer R., O’Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56. [PubMed]
57. Jang P.G., Namkoong C., Kang G.M., Hur M.W., Kim S.W., Kim G.H. NF-kappaB activation in hypothalamic pro-opiomelanocortin neurons is essential in illness- and leptin-induced anorexia. J Biol Chem. 2010;28:9706–9715. [PMC free article] [PubMed]
58. Yamawaki Y., Kimura H., Hosoi T., Ozawa K. MyD88 plays a key role in LPS-induced Stat3 activation in the hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2010;298:R403–R410. [PubMed]

Articles from The Japanese Dental Science Review are provided here courtesy of Elsevier